Trial Profile
A Phase III Open-Label Extension Study to Investigate the Safety of SER120 Nasal Spray Formulations in Patients With Nocturia Completing Study SPC-SER120-DB1-200901 or Study SPC-SER120-DB2-200902
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2021
Price :
$35
*
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Adverse reactions; Registrational
- Sponsors Serenity Pharmaceuticals Corporation
- 18 Jul 2012 New trial record